Strike While the Iron is Hot: Changing the Rules in Essential Health R&D is Urgently Needed,and is within Reach

Abstract

The view that strong intellectual property (IP) protection is necessary for drug development forms the backbone of the current health research and development paradigm. But the evidence shows how this system is fundamentally flawed. Neglected diseases, which count for 12 per cent of the disease burden, but for only 1 per cent of all drugs developed, are an example. The World Health Organization (WHO) Commission on Intellectual Property, Innovation and Public Health is a significant addition to this body of evidence. The report outlines how, despite ever stronger IP regimes through the implementation of the Trade-Related Aspects of Intellectual Property Agreement, the quality and quantity of medical innovation is declining. The report concludes that innovation is meaningless if the products developed can not be accessed by those who need them most. It calls for a global plan of action to identify mechanisms that will stimulate the discovery, development and delivery of health tools that address diseases affecting the poor. In a resolution adopted at the 2006 World Health Assembly, countries took heed of this call and committed to looking at ‘securing an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries’. Governments, and the WHO, must not squander this opportunity.

Keywords

intellectual property research & development access to medicines global framework TRIPS CIPIH

Get full access to this article

View all access options for this article.

References

Olesen

O. F.

Hoeveler

(2005). How can the industrial world help to implement new vaccines against poverty-related diseases?, in Kaufmann

S.H.

Lambert

P.-H.

(eds.), The grand challenge for the future: Vaccines for poverty-related diseases from bench to field, Birkhauser, Basel, Switzerland.

Chirac

Torreele

(2006). Global framework on essential health R&D. Lancet 367, 1560–1561.

Prescrire Editorial Team (2005). A review of new drugs in 2004: Floundering innovation and increased risk-taking. Prescrire Int. 14(76), 68–73.

Barer

M. L.

Caetano

P. A.

Black

C. D.

Morgan

S. G.

Bassett

K. L.

Wright

J. M.

Evans

R. G.

(2005). Breakthrough drugs and growth in expenditure on prescription drugs in Canada. Br. Med. J. 331, 815–816.

The National Institute for Health Care Management Research and Educational Foundation (2002). Changing patterns of pharmaceutical innovation. Available from http://www.nihcm.org/innovations.pdf, accessed 25th September 2006.

Commission on Intellectual Property Rights (2002). Integrating intellectual property rights and development policy. Available from http://www.iprcommission.org/graphic/documents/final_report.htm, accessed 25th September 2006.

Commission on Intellectual Property Rights, Innovation and Public Health (2006). Public health, innovation, and intellectual property rights. WHO, available from http://www.who.int/intellectualproperty/documents/thereport/en/index.html, accessed 25th September 2006.

Fifty-ninth World Health Assembly (2006). World Health Assembly Resolution 59/24: Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action. WHO, available from http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_R24-en.pdf#search=%22Public%20health%2C%20innovation%2C%20essential%20health%20research%20and%20intellectual%20property%20rights%3A%20towards%20a%20global%20strategy%20and%20plan%20of%20action%22, accessed 25th September 2006.